Systemic Probiotics in the Periodontal Treatment

Clinical, Microbiological and Immunological Evaluation of the Effects of Systemic Probiotics in the Periodontal Treatment

The aim of this multicenter randomized clinical trial is to evaluate the clinical, microbiological and immunological effects of probiotics as an adjunct to Scaling and Root Planing alone or in combination with Metronidazole and Amoxicillin in the treatment of periodontitis.

Study Overview

• Status: Unknown
• Conditions: Periodontitis
• Intervention / Treatment: Procedure: Scaling and root planing; Drug: Metronidazole and Amoxicillin placebos; Dietary supplement: Probiotic placebo; Dietary supplement: Probiotic; Drug: Metronidazole; Drug: Amoxicillin

Detailed Description

The association of scaling and root planing (SRP) with systemic metronidazole (MTZ) and amoxicillin (AMX) has been advocated as one of the most promising therapeutic protocol for the treatment of advanced periodontitis, since the early 2000's. More recently, probiotics has also been suggested as a promising adjunctive treatment for periodontitis due to their antimicrobial and anti-inflammatory properties. Therefore, the aim of this study is to evaluate the clinical, microbiological and immunological effects of probiotics as an adjunct to SRP alone or in combination with MTZ and AMX in the treatment of periodontitis. In this randomized, double-blind, placebo-controlled trial, subjects with periodontitis will be randomly assigned to receive (i) SRP alone, or combined with: (ii) two probiotics lozenges a day for 90 days (Prob), (iii) 400 of MTZ, plus AMX (500 mg) thrice a day (TID) for 14 days (MTZ+AMX), or (iv) Prob and MTZ+AMX. Subjects will be monitored up to 1 year post-therapy. Nine subgingival plaque samples will be collected at baseline and at 3, 6 and 12 months post-therapy; three samples in each of the following pockets categories: shallow (probing depth [PD]≤3 mm), moderate (PD=4-6 mm) and deep (PD≥7 mm). The microbiological samples will be analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species. Two non-contiguous diseased sites (i.e PD and CAL ≥ 5mm, bleeding and probing [BOP] and no furcation involvement) and two non-contiguous healthy sites (i.e. PD and clinical attachment level [CAL] ≤ 4 mm without BoP and/or marginal bleeding) will be randomly chosen per patient for gingival crevicular fluid (GCF) sampling, from the same sites selected for the microbiological monitoring. Peripheral blood samples will also be collected one week after clinical examination. The GCF and blood samples will be analyzed using a multi-analyte method by means of a 17-multiplex fluorescent bead-based immunoassay for 17 cyto/chemokines. The significance of differences over the course of the study will be sought using repeated measures ANOVA and Tukey multiple comparison tests, and at each time point (among groups) using either ANOVA and Tukey multiple comparison tests or ANCOVA with adjustments for the baseline values. The Chi-square test will be used to compare the differences in the frequency of gender, and to compare the differences in the frequency of subjects achieving the clinical endpoint at 1 year and of self-perceived adverse effects. A stepwise forward logistic regression analysis will be performed in order to investigate the impact of predictor variables on the clinical endpoint for treatment, i.e., "presence of ≤4 sites with PD≥5 mm at 12 months post-therapy (yes/no)". The Number Needed to Treat (NNT) with adjunctive antibiotic in order to obtain treatment success (≤4 sites with PD ≥5 mm) will be calculated. The level of significance will be set at 5%.

• Study Type: Interventional
• Enrollment (Anticipated): 176
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • Paraná
    • Curitiba, Paraná, Brazil, 80210170
      • Recruiting
      • Federal University of Parana
      • Contact: Geisla Soares, Professor; Phone Number: +55 (41) 33604134; Email: geisla.soares@ufpr.br
      • Contact: Natalie Temporão, Master student; Phone Number: +55 (41) 99960339; Email: natalie.temporao@gmail.com
  • São Paulo
    • Guarulhos, São Paulo, Brazil, 07023-070
      • Not yet recruiting
      • University of Guarulhos
      • Contact: Belén Retamal-Valdes, Professor; Phone Number: +55 (11) 942801064; Email: belenretamalvaldes@gmail.com
      • Contact: Magda Feres, Professor; Email: mferes@ung.br
      • Sub-Investigator: Luciene Figueiredo, Professor
      • Sub-Investigator: Marcelo Faveri, Professor
      • Sub-Investigator: Poliana Duarte, Professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ≥30 years of age;
• at least 15 teeth (excluding third molars and teeth with advanced decay indicated for extraction);
• a minimum of 6 teeth with at least one site each with probing depth (PD) and clinical attachment level (CAL) ≥5 mm;
• at least 30% of the sites with probing depth (PD) and clinical attachment level (CAL) ≥4 mm and bleeding on probing (BOP);

Exclusion Criteria:

• pregnancy;
• breastfeeding;
• current smoking and former smoking within the past 5 years;
• systemic diseases that could affect the progression of periodontitis (e.g. diabetes, immunological disorders, osteoporosis);
• scaling and root planing an in the previous 12 months;
• antibiotic therapy in the previous 6 months;
• long-term intake of anti-inflammatory medications;
• need for antibiotic pre-medication for routine dental therapy;
• use of orthodontic appliances;
• extensive dental prosthetic rehabilitation;
• allergy to metronidazole and/or amoxicillin.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control; Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.	Procedure: Scaling and root planing; SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.; Other Names: SRP; Drug: Metronidazole and Amoxicillin placebos; Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).; Dietary supplement: Probiotic placebo; The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
Experimental: Probiotic; Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.	Procedure: Scaling and root planing; SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.; Other Names: SRP; Drug: Metronidazole and Amoxicillin placebos; Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).; Dietary supplement: Probiotic; The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
Experimental: Antibiotic; Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.	Procedure: Scaling and root planing; SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.; Other Names: SRP; Drug: Metronidazole; Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).; Drug: Amoxicillin; Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
Experimental: Antibiotic + probiotic; Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.	Procedure: Scaling and root planing; SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.; Other Names: SRP; Dietary supplement: Probiotic placebo; The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.; Drug: Metronidazole; Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).; Drug: Amoxicillin; Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of subjects reaching ≤ 4 periodontal sites with probing depth (PD) ≥ 5 mm at 12 months	12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of sites with PD ≥ 5 mm.	Baseline, 3, 6 and 12 months
Number of sites with PD ≥ 6 mm.	Baseline, 3, 6 and 12 months
Number of sites with PD ≥ 7 mm.	Baseline, 3, 6 and 12 months
Change in the number of sites with PD ≥ 5 mm.	Baseline, 3, 6 and 12 months
Change in the number of sites with PD ≥ 6 mm	Baseline, 3, 6 and 12 months
Change in the number of sites with PD ≥ 7 mm	Baseline, 3, 6 and 12 months
Mean PD changes in sites with initial PD between 4-6 mm	Baseline - 12 months
Mean PD changes in sites with initial PD ≥ 7 mm.	Baseline - 12 months
Mean CAL changes in sites with initial CAL between 4-6 mm	Baseline - 12 months
Mean CAL changes in sites with initial CAL ≥ 7 mm.	Baseline - 12 months
Full-mouth Probing Depth (mm).	Baseline, 3, 6 and 12 months
Full-mouth Clinical Attachment Level (mm)	Baseline, 3, 6 and 12 months
Percentage of sites with bleeding on probing	Baseline, 3, 6 and 12 months
Percentage of sites with plaque accumulation	Baseline, 3, 6 and 12 months
Percentage of sites with marginal bleeding	Baseline, 3, 6 and 12 months
Occurrence of headache obtained through a questionnaire of adverse effects	14 days after taking antibiotic
Occurrence of headache obtained through a questionnaire of adverse effects	90 days after taking probiotic
Occurrence of vomiting obtained through a questionnaire of adverse effects	14 days after taking antibiotic
Occurrence of vomiting obtained through a questionnaire of adverse effects	90 days after taking probiotic
Occurrence of diarrhea obtained through a questionnaire of adverse effects.	14 days after taking antibiotic
Occurrence of diarrhea obtained through a questionnaire of adverse effects.	90 days after taking probiotic
Occurrence of nausea obtained through a questionnaire of adverse effects.	14 days after taking antibiotic
Occurrence of nausea obtained through a questionnaire of adverse effects.	90 days after taking probiotic
Proportions of periodontal pathogenic bacterial species.	Baseline, 3, 6 and 12 months
Counts of periodontal pathogenic bacterial species.	Baseline, 3, 6 and 12 months
Counts of chemokines in the crevicular gingival fluid.	Baseline and 12 months
Counts of chemokines in the peripheral blood samples	Baseline and 12 months

Collaborators and Investigators

• Sponsor: Belén Retamal-Valdes
• Investigators: Principal Investigator: Magda Feres, Professor, University of Guarulhos

Publications and helpful links

General Publications

• Feres M, Figueiredo LC, Soares GM, Faveri M. Systemic antibiotics in the treatment of periodontitis. Periodontol 2000. 2015 Feb;67(1):131-86. doi: 10.1111/prd.12075.
• Feres M, Soares GM, Mendes JA, Silva MP, Faveri M, Teles R, Socransky SS, Figueiredo LC. Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2012 Dec;39(12):1149-58. doi: 10.1111/jcpe.12004. Epub 2012 Sep 27.
• Borges I, Faveri M, Figueiredo LC, Duarte PM, Retamal-Valdes B, Montenegro SCL, Feres M. Different antibiotic protocols in the treatment of severe chronic periodontitis: A 1-year randomized trial. J Clin Periodontol. 2017 Aug;44(8):822-832. doi: 10.1111/jcpe.12721. Epub 2017 Jul 26.
• Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, Slomka V, Quirynen M, Alkaya B, Teughels W. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015 Nov;42(11):1032-41. doi: 10.1111/jcpe.12464. Epub 2015 Nov 29.
• Retamal-Valdes B, Teughels W, Oliveira LM, da Silva RN, Fritoli A, Gomes P, Soares GMS, Temporão N, Furquim CP, Duarte PM, Doyle H, Faveri M, Figueiredo LC, Feres M. Clinical, microbiological, and immunological effects of systemic probiotics in periodontal treatment: study protocol for a randomized controlled trial. Trials. 2021 Apr 15;22(1):283. doi: 10.1186/s13063-021-05246-0.

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2018
• Primary Completion (Anticipated): December 30, 2020
• Study Completion (Anticipated): December 30, 2021

Study Registration Dates

• First Submitted: November 5, 2018
• First Submitted That Met QC Criteria: November 5, 2018
• First Posted (Actual): November 7, 2018

Study Record Updates

• Last Update Posted (Actual): January 13, 2020
• Last Update Submitted That Met QC Criteria: January 8, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Metronidazole; Periodontitis; Probiotic; Amoxicillin; Scaling and root planing; Periodontal treatment
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Periodontal Diseases; Mouth Diseases; Periodontitis; Anti-Infective Agents; Anti-Bacterial Agents; Antiprotozoal Agents; Antiparasitic Agents; Metronidazole; Amoxicillin
• Other Study ID Numbers: CAAE: 74049717.7.1001.5506

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No